Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape.
The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial.
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor.
Sarcomas are relatively rare malignant tumors that arise from mesenchymal cells and therefore encompass a variety of histologies and can occur in any anatomic compartment. The incidence of sarcoma is estimated at 1% of all new cancer diagnoses in the United States annually. Approximately 15% of soft tissue sarcomas occur in the retroperitoneum, with about 1600 new retroperitoneal sarcoma cases diagnosed in the United States each year.
Using RNA sequencing for individual pediatric cancer cases could more effectively target gene expression in tumors.
A 51-year-old man noticed abdominal swelling and distention with intermittent abdominal pain, early satiety, and decreased appetite over the past several months. A computed tomography scan of the abdomen is performed. What's your diagnosis?
New hope for advanced sarcomas
Naveed Saleh, MD, MS
Dr. von Mehren discusses current considerations and challenges in the management of patients with soft tissue sarcoma, as well as recent clinical trial data.
A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.
A new study evaluated whether busulfan and melphalan improve EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction.